drugset

drugset / Trial / NCT06701721

A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy.

NCT06701721 ↗

Phase 1 Recruiting 21 enrolled Therini Bio Pty Ltd Therini Bio, Inc. · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

THN391-OPT-101 is a study assessing safety and preliminary efficacy of THN391 in patients with diabetic macular edema (DME) given as monotherapy.

Timeline

Start: 2024-12-20
Primary completion: 2027-03-31
Completion: 2027-05-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	THN391	Unknown	—	Intravitreal

Indications